Wet Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Wet Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH
Vabysmo (faricimab) has been authorised by the EMA for indications including wet age-related macular degeneration, macular edema, and diabet…
-
EMA approval · 2026-08-21EMA Authorised: Eylea (aflibercept) — Bayer AG
EMA authorises Eylea (aflibercept) for multiple ocular conditions including wet age-related macular degeneration and diabetic eye diseases.
-
EMA approval · 2026-06-15EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
The EMA authorises Rimmyrah (ranibizumab) by Qilu Pharma Spain S.L. for multiple ophthalmic indications including wet age-related macular de…
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK [Phase 3]
Phase 3 study evaluating Tarcocimab Tedromer and Tabirafusp Tedromer versus Aflibercept in wet age-related macular degeneration; status ACTI…
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Update: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD [Phase 2, Phase 3]
Pivotal Phase 2/3 study of ABBV-RGX-314 (RGX-314) gene therapy for neovascular age-related macular degeneration evaluates subretinal deliver…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-24EMA Authorised: Ranluspec (ranibizumab) — Lupin Europe GmbH
EMA authorised Ranluspec (ranibizumab) from Lupin Europe GmbH. The product is indicated for several retinal conditions including wet age-rel…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) [Phase 2, Phase 3]
EyeBiotech's MK-8748 (EYE201) is in a Phase 2/3 trial for macular degeneration, including age-related macular degeneration, with recruitment…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) [Phase 2, Phase 3]
Phase 2/3 trial MK-8748 (EYE201) for age-related macular degeneration is described in this update. The study status is not yet recruiting.
-
EMA approval · 2026-04-14EMA Authorised: Pavblu (aflibercept) — Amgen Technology (Ireland) UC
EMA has authorised Pavblu (aflibercept) by Amgen Technology (Ireland) UC for multiple ocular indications including wet age-related macular d…
-
EMA approval · 2026-04-10EMA Authorised: Mynzepli (aflibercept) — Advanz Pharma Limited
The European Union has authorised Mynzepli (aflibercept) from Advanz Pharma Limited for multiple retinal diseases, including wet age-related…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: NT-101 Topical Ophthalmic Solution in Patients With Wet AMD [Phase 1, Phase 2]
This is a clinical trial update for NT-101 Topical Ophthalmic Solution in patients with wet age-related macular degeneration, covering Phase…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 [Phase 3]
Phase 3 clinical trial update for EYP-1901 in wet age-related macular degeneration; primary efficacy to be determined at Week 56 in a 2-year…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: MMP-9 Inhibition for Recalcitrant Wet AMD [Phase 2]
Phase 2 clinical trial investigating inhibitors of MMP-9 for recalcitrant wet age-related macular degeneration; currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 [Phase 3]
A Phase 3 trial (LUCIA) evaluating EYP-1901 for wet age-related macular degeneration is ongoing, with primary efficacy to be determined at W…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy [Phase 2]
A Phase 2 study of SCD411 in adults with wet age-related macular degeneration, retinal vein occlusion, diabetic macular edema, or diabetic r…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) [Phase 3]
Phase 3 trial AQUARIUS is evaluating the efficacy and safety of Ixo-vec (Ixoberogene soroparvovec) in neovascular/wet age-related macular de…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR) [Phase 3]
A Phase 3 clinical trial assessing the efficacy and safety of LX102 Gene Therapy for neovascular age-related macular degeneration (nAMD) is …
-
EMA approval · 2026-03-04EMA Authorised: Eylea (aflibercept) — Bayer AG
The EMA authorised Eylea (aflibercept) from Bayer AG for multiple ocular indications, including wet age-related macular degeneration, macula…
-
EMA approval · 2026-03-03EMA Authorised: Afqlir (aflibercept) — Sandoz GmbH
The EMA authorised Afqlir (aflibercept) from Sandoz GmbH for retinal conditions including wet age-related macular degeneration, macular edem…
-
EMA approval · 2026-02-25EMA Authorised: Byooviz (ranibizumab) — Samsung Bioepis NL B.V.
EMA authorised Byooviz (ranibizumab) from Samsung Bioepis NL B.V. for multiple retinal diseases, including wet age-related macular degenerat…
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
This entry provides an update on the OPTIC-EXT long-term extension study of ADVM-022 for wet age-related macular degeneration. The trial is …
-
EMA approval · 2026-02-09EMA Authorised: Lytenava (bevacizumab) — Outlook Therapeutics NL B. V.
The EMA authorised Lytenava, a bevacizumab-based treatment for wet age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) [Phase 3]
A Phase 3 study comparing JL14002 to Lucentis for wet age-related macular degeneration has completed.
-
EMA approval · 2026-01-27EMA Authorised: Beovu (brolucizumab) — Novartis Europharm Limited
The European Medicines Agency authorised Beovu (brolucizumab) by Novartis Europharm Limited for the treatment of wet age-related macular deg…
-
EMA approval · 2026-01-19EMA Authorised: Opuviz (aflibercept) — Samsung Bioepis NL B.V.
EMA authorised Opuviz (aflibercept) by Samsung Bioepis NL B.V. for treating several retinal conditions including wet age-related macular deg…